Lecanemab and donanemab (Kisunla), another anti-amyloid treatment, won approval based on evidence that they slowed cognitive ...

Looking at surging obesity drug sales, market share momentum, and an increased fair value estimate, here’s what we think of ...

pointing out that the drug has already been approved in the US, China, Japan, and other world markets for people with the early signs of Alzheimer's. "Lilly remains confident in the safety and ...

Lilly has said that its drug has advantages over Leqembi ... very meaningful results for people with early symptomatic Alzheimer's disease and can now help to improve the standard of care for ...

A world-leading experimental dementia drug designed to prevent the disease before it begins will be trialled in Australia for ...

NewLimit, an anti-aging biotech startup backed by Coinbase CEO Brian Armstrong, raised a $130 million Series B round.

Officials from the Indianapolis-based drugmaker said the Lilly Medicine Foundry will help streamline the process of ...

To more effectively treat neurodegenerative conditions, we first need diagnostic tools that lend a more complete picture of ...

People taking Eli Lilly's obesity drug, Zepbound, lost nearly 50 per cent more weight than those using rival Novo Nordisk's Wegovy.

Novo Nordisk A/S' Q1 earnings reveal strong growth in semaglutide-driven sales despite a slight revenue miss. Learn more ...

Alzheimer's disease is the most common form of dementia. “Let’s actually stop those plaques from forming,” she said. The new drug was developed by Eli Lilly, the same company behind ...

By improving insulin sensitivity and potentially interacting with receptors involved in learning and brain cell protection, semaglutide could potentially slow the progression of Alzheimer's disease.